Severe Adenovirus Pneumonia Requiring Extracorporeal Membrane Oxygenation Support in Immunocompetent Children

Xuefei Chen¹, Jianhai Lv²,³, Lu Qin², Chaochun Zou¹ and Lanfang Tang²*

¹ Department of Endocrinology, The Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China, ² Department of Pulmonology, The Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China, ³ Department of Pediatrics, Shangyu People’s Hospital, Shaoxing, China

Objective: To highlight severe adenovirus pneumonia in immunocompetent patients by analysis of severe adenovirus pneumonia associated with acute respiratory distress syndrome in whom extracorporeal membrane oxygenation (ECMO) support is required.

Methods: Pediatric patients with adenovirus pneumonia and ECMO supports in our hospital from February 2018 to May 2019 were retrospectively analyzed, and having 100 common adenovirus pneumonia children as a control.

Results: A total of 8 patients, including 4 boys (50.0%), were enrolled. They were previously immunocompetent with a median age of 31 months. They were admitted as persistent fever and cough for more than one week. Median time prior to development of respiratory failure requiring intubation and invasive mechanical ventilation was 5 days. Venoarterial ECMO support as rescue ventilation was instituted after a median time of 24.5 h of conventional mechanical ventilator support. The median duration on ECMO support was 9 days and mechanical ventilation was 14 days, respectively. Six patients (75%) were recovered and 2 (25%) died. Median length of stay in ICU and hospital were 27.5 days and 47.5 days, respectively.

Conclusion: The promising outcomes of our cases suggested that ECMO support for rescue ventilation may be considered when symptoms deteriorated in adenovirus pneumonia patients, and may improve outcome. However, sequelae of adenovirus pneumonia and ECMO-related complications should also be taken into account.

Keywords: adenovirus pneumonia, extracorporeal membrane oxygenation, acute respiratory distress syndrome, survival rate, risk factors

INTRODUCTION

Human adenoviruses (HAdVs) are non-enveloped DNA viruses associated with a wide range of clinical manifestations (1). HAdVs infections occur primarily in children younger than 5 years of age and account for 2–5% of all pediatric respiratory illnesses and 4–10% of childhood pneumonias (2, 3). In China, HAdVs have caused respiratory tract infections outbreaks and several cases
A total of 8 patients admitted to our unit with severe adenovirus pneumonia in the 175 autopsied pulmonary tissues of pediatric fatal pneumonia in South China showed the positive percentage of adenovirus was 9.14% (11). To date, at least 67 immunologically distinct serotypes of HAdVs have been recognized and classified into 7 subgroups (A-G) based on hemagglutinin properties, DNA homology and biochemical characteristics (12). HAdVs serotypes 3, 7, 21 and 55 appear to be most commonly associated with severe lower respiratory tract infections in children (13–15).

Adenovirus pneumonia was speculated to occur in two phases (16). Acute extensive pulmonary consolidation mimicking the bacteria pneumonia and accompanying systemic compromise characterized by multi-organ damage, caused significant morbidity and considerable mortality (15, 17). A chronic phase characterized by persistent wheezing and crackles was followed in some cases, sometimes severe enough to require mechanical ventilation support or extracorporeal life support, and development of bronchiectasis, necrotizing pneumonia, bronchiolitis obliterans (BO), atelectasis, and cor pulmonale (18–21). It can incite intensive and continuous infection with the utilization of a detective or compromised immune system sometimes resulting in lethality (1). Life-threatening adenovirus pneumonia has previously been described in immunocompromised patients (22, 23), but was relatively rare in immunocompetent individuals (1, 16). Extracorporeal membrane oxygenation (ECMO) was first introduced in 1970 as a means of cardiopulmonary support for patients with potentially reversible cardiac and/or respiratory failure in whom maximal conventional ventilator strategies have been exhausted (24). The successful use of ECMO in patients with severe hypoxemic respiratory failure during the influenza pandemic (25, 26) has increased the practice of this salvage therapy over the past decade (27). However, ECMO used to support life-threatening adenovirus pneumonia was rarely reported. Here, we report 8 cases of severe adenovirus pneumonia associated with acute respiratory distress syndrome (ARDS) in whom conventional mechanical ventilation failed and required ECMO support to highlight this rare condition, and set a comparison group to reveal the risk factors of severe adenovirus pneumonia requiring ECMO support.

MATERIALS AND METHODS

Objectives

A total of 8 patients admitted to our unit with severe adenovirus pneumonia requiring ECMO support from February 2018 to May 2019 were retrospectively analyzed. Clinical data, including demographic characteristics (age and gender), clinical symptoms and signs, laboratory data, microbiological findings, imaging examinations, complications, treatments, and outcomes, were collected and analyzed. A random group of 100 children extracted from a total of 763 patients with common adenovirus pneumonia hospitalized during the same period was involved as a control. The 100 children were all previously healthy and the one who required ECMO support was excluded. The requirement for informed consent by individual patients was waived given the retrospective nature of the study.

Diagnostic Methods

Nasopharyngeal swab samples, sputum, bronchoalveolar lavage fluid (BALF), pleural fluid samples and/or serum were collected for microbiological tests including immunofluorescence staining, antigen and antibody tests, nucleic acid detection and bacterial culture. Pathogen high-throughput genome sequencing (BGI, Inc, China) of BALF was performed in 3 patients to screen for bacteria, viruses, fungi, parasites, mycobacterium tuberculosis complex, mycoplasma, and chlamydia.

Adenovirus pneumonia was diagnosed based on the presence of adenovirus detected in BALF, pleural fluid or nasopharyngeal swab samples by immunofluorescence microscopy, measurement of antibodies in paired serum samples or molecular methods, and chest radiographic changes combined with the presence of attributable symptoms and signs. ARDS was diagnosed according to the consensus recommendations from the Pediatric Acute Lung Injury Consensus Conference (28), and mechanical ventilation would be considered early in children at risk for ARDS. There was no worldwide consensus for definite parameters or clinical conditions that ECMO should be initiated. In our unit, ECMO will be considered in respiratory failure not responding to conventional ventilator and pharmacologic therapies.

Statistical Analyses

Measurement variables were summarized using median or mean and ranges, and enumeration variables using frequencies and percentages. Student’s t-test or the Mann-Whitney U-test was used to compare measurement variables. Chi-square test was used to test for enumeration variables. A p < 0.05 was considered significant. Statistical analysis was performed by SPSS software, version 20.0.

RESULTS

Clinical and Laboratory Data

All 8 patients were previously healthy immunocompetent children without any underlying diseases. They were 4 boys (50.0%) and 4 girls with a median age of 31 months (range, 13 months to 61 months). Except one patient was born at 35 weeks due to premature rupture of membranes, the others were born at term. All individuals were born by vaginal delivery without history of asphyxia at birth.

Fever and cough over one week were presented in all 8 patients with a mean maximum body temperature of 40.2°C (range, 39.8–40.9°C) at the onset of illness. All patients had tachypnea and 3 had wheeze when admitted to hospital. Rales and “three concave sign” were noted in 5 patients. Decreased breath sounds were observed in 2 patients. Neurological manifestations, such as drowsiness, were observed in 2 patients while positive Babinski sign in one. White blood cell counts of them were low or within the normal rage while lymphopenia occurred in 6 and thrombocytopenia in 2 patients. C-reactive protein and procalcitonin levels were elevated in 6 and 7 patients with
the median value of 53.0 µg/L and 4.5 µg/L, respectively. Elevated lactate dehydrogenase was found in all 8 patients with the median value of 1458.5 U/L, and 4 patients over 1,000 U/L. Markedly raised levels (greater than twice the normal) of alanine aminotransferase, creatinine, and creatine kinase-MB were observed in one, one and 2 patients with the maximum value of 171, 169, and 161 U/L, respectively (Table 1).

All 8 patients progressed to respiratory failure and complicated by ARDS in the early course of the disease. Arterial blood gas analysis taken before ECMO implementation revealed profound hypoxia with a median oxygen index of 23.75 (range, 5.0–52.6). Multiple organ failure was detected in 3 patients. Almost all the patients developed extrapulmonary manifestations, common in central nervous system (toxic encephalopathy in 4), digestive system (liver function lesion in 3; peptic ulcer, alimentary tract hemorrhage and pancreatitis in one, respectively), circulatory system (heart failure in 3, arrhythmia in 1), urinary system (acute renal failure in 2), hematologic system (anemia in 3, leukopenia in 3, thrombocytopenia in 4), and others including polyserous effusions in 8 and hypoproteinemia in 4 (Table 2).

Microbiological Data
Bronchoscopy with bronchial washings was performed in all 8 patients. HAdVs were detected in BALFs of 7 patients and nasopharyngeal swab sample of one patient by immunofluorescence assay. DNA of HAdVs was isolated in 3 patients (patient 1, 4, and 5) and genotyping revealed HAdV-7 for these 3 patients. Co-infections with Mycoplasma, Stenotrophomonas maltophilia, Klebsiella pneumoniae, Acinetobacter baumannii, Aspergillus fumigatus or influenza A virus were observed in 5 patients (Table 2).

Radiographic Imaging
Chest X-ray and computed tomography (CT) scans revealed bilateral lobar or multifocal consolidations and air bronchogram in the lungs of all 8 patients, and radiographic lesions progressed rapidly after admission (Figures 1–8). Atelectasis and bronchiectasis were observed in 5 and 4 patients, respectively. Pulmonary fibrosis was identified in one patient. Pleural effusion was noted in all 8 patients. Consolidations and pleural effusion occurred almost simultaneously. The duration from onset of fever to development of pleural effusion ranged from 10 to 18 days with a mean duration of 15 days.

Treatment and Outcome
Based on the seasonal outbreak and clinical and laboratory findings suggesting viral pneumonia, five patients were empirically treated with antiviral medications, including oseltamivir alone in 4 patients and oseltamivir combined with acyclovir in one patient. Empiric broad-spectrum antibiotics were initially administered but deescalated when microbiology results were available. Immunoglobulin was administered in the early course and periodically thereafter, in total doses varying between 2 and 4 g/kg. All the patients received steroid therapy. Continuous renal replacement therapy treatment was instituted in 2 patients (patient 4 and 5) for acute renal failure (Table 2).
| No. | Radiographic manifestations                      | OI  | Duration of dyspnea to IMV* | Duration of IMV* | Duration of IMV to ECMO† | IVIG (g/kg) | CRRT* | Antiviral agent | Serotype | Coinfection | Duration of ICU* | Duration of hospitalization* | Main complications and sequelae | Outcomes                  |
|-----|-----------------------------------------------|-----|----------------------------|------------------|--------------------------|-------------|--------|----------------|----------|-------------|----------------|--------------------------|-------------------------------|---------------------------|
| 1   | Consolidations, pleural effusion              | 12.8| 5                          | 12               | 45.5                     | 7           | 2      | Oseltamivir     | 7        | Negative    | 25             | 39                       | Plastic bronchitis, encephalatrophy | Survival                  |
| 2   | Consolidations, pleural effusion, atelectasis, bronchiectasis | 18.9| 5                          | 13               | 22                       | 9           | 2      | Oseltamivir     | NA       | Influenza A virus, Mycoplasma | 23             | 36                       | BO, hypertension              | Survival                  |
| 3   | Consolidations, pleural effusion              | 28.6| 7                          | 15               | 24                       | 8           | 4      | Oseltamivir     | NA       | Stenotrophomonas maltophilia | 42             | 77                       | BO, MOF, pancreatitis          | Survival                  |
| 4   | Consolidations, pleural effusion, atelectasis | 5.0 | 2                          | 26               | 31                       | 9           | 2.5    | None           | 7        | Negative    | 49             | 56                       | BO, MOF, pneumonia, cognitive dysfunction | Survival                  |
| 5   | Consolidations, pleural effusion, bronchiectasis, pulmonary fibrosis | 18.4| 1                          | 86               | 4                        | 86          | 2      | Acyclovir, oseltamivir | 7        | Mycoplasma, Aspergillus fumigatus | 88             | 86                       | MOF, pneumonia               | Death (MOF)                |
| 6   | Consolidations, pleural effusion, atelectasis, bronchiectasis | 48.8| 9                          | 15               | 6                        | 12          | 2.5    | None           | NA       | Klebsiella pneumoniae | 27             | 58                       | BO                          | Survival                  |
| 7   | Consolidations, pleural effusion, atelectasis | 51.4| 4                          | 12               | 25                       | 9           | 2      | None           | NA       | Negative    | 28             | 28                       | BO, circuit clotting           | Survival                  |
| 8   | Consolidations, pleural effusion, atelectasis | 52.6| 17                         | 12               | 42                       | 10          | 2      | Oseltamivir     | NA       | Mycoplasma, Acinetobacter baumannii | 12             | 28                       | Pneumorrhagia                | Death (ARDS)               |

OI: oxygen index; *day; †hour; IMV, invasive mechanical ventilation; ECMO, extracorporeal membrane oxygenation; IVIG, intravenous immunoglobulin; CRRT, continuous renal replacement therapy; NA, not available; ICU, intensive care unit; BO, bronchiolitis obliterans; MOF, multiple organ failure; ARDS, acute respiratory distress syndrome.
The median duration prior to development of respiratory failure requiring intubation and invasive mechanical ventilation was 5 days. Venoarterial ECMO supports as rescue ventilation was instituted after the median time of 24.5 h of conventional mechanical ventilator support. The median duration on ECMO support and mechanical ventilation were 9 and 14 days, respectively. Median length of stay in ICU and hospital were 27.5 and 47.5 days, respectively (Table 2). The oxygenation response to ECMO was shown in Table 3.

Some complications, including bleeding, infection, pneumothorax, circuit cloting, hypertension, neurological dysfunction and acute kidney injury, were noted during ECMO support (Table 2). Unfortunately, two patients (25.0%) died. A 52-month-old girl (patient 5) received 86 days of ECMO and mechanical ventilator support, but pulmonary imaging showed progressive exacerbation of pulmonary fibrosis. Although lung transplantation was conducted on the day 78 of ECMO therapy, she eventually died of multi organ failure. Another 30-month-old boy (patient 8) received 10 days of ECMO support and 12 days of mechanical ventilator support. However, he manifested coagulation dysfunction together with progressively decreasing oxygen saturation. Finally, his parents gave up all the treatments, and the patients passed away after staying in hospital for 28 days (Table 2).

Duration of follow-up was 7-22 months for the 6 survivors. Recurrent cough or wheezing was infrequent. BO was observed in 5 of the 6 survivors. Plastic bronchitis was found by flexible bronchoscopy and confirmed by pathological examination in patient 1. Other residual pulmonary diseases, such as atelectasis,
necrotizing pneumonia and bronchiectasis, were found in one, one and 3 patients, respectively.

Risk Factors Analysis
The demographic and clinical features of the severe adenovirus pneumonia group were compared with those in the common adenovirus pneumonia group (Table 4). Severe adenovirus pneumonia group showed older age ($p = 0.005$), lower white blood cell levels ($p = 0.008$), higher C-reactive protein ($p = 0.022$), procalcitonin ($p = 0.001$), and lactate dehydrogenase ($p = 0.001$) levels. Pleural effusion ($p < 0.001$) was seen more frequently in the severe adenovirus pneumonia group. There is no difference of sex or maximum body temperature between these two groups.

DISCUSSION
We reported 8 immunocompetent patients of severe adenovirus pneumonia associated with ARDS in whom ECMO support was required, and showed a promising survival rate of 75%. Furthermore, to our knowledge, this is the first retrospective observational study on the comparison of clinical manifestations between severe adenovirus pneumonia requiring ECMO support and common adenovirus pneumonia. In this regard, several findings are noteworthy. (1) HAdV could cause severe adenovirus pneumonia accompanied by ARDS in
TABLE 3 | Oxygenation response to extracorporeal membrane oxygenation support.

| No | ECMO model | Mechanical ventilation settings | Pre-ECMO arterial blood gas analysis | Mechanical ventilation settings | Post ECMO weaning arterial blood gas analysis |
|----|------------|---------------------------------|-------------------------------------|---------------------------------|--------------------------------------------|
|    |            | pre-ECMO                        |                                     | post ECMO                        |                                            |
|    |            | Ventilator type     | PEEP (cmH₂O) | FIO₂ (%) | pH | PaO₂ (mmHg) | PaCO₂ (mmHg) | SpO₂ (%) | Ventilator type | PEEP (cmH₂O) | FIO₂ (%) | pH | PaO₂ (mmHg) | PaCO₂ (mmHg) | SpO₂ (%) |
| 1  | Medos 2400 | SIMV                           | 3                                     | 1                                 | 7.256 | 46.9 | 66.8 | 83 | SIMV               | 7 | 0.55 | 7.256 | 92.9 | 58.3 | 97 |
| 2  | Medos 2400 | SIMV                           | 13                                    | 1                                 | 7.473 | 58.2 | 41.2 | 78 | SIMV               | 8 | 0.7 | 7.329 | 99.2 | 46.1 | 97 |
| 3  | Sorin      | SIMV                           | 8                                     | 0.98                              | 7.471 | 48   | 47.1 | 86 | SIMV               | 6 | 0.7 | 7.525 | 153  | 33.2 | 99 |
| 4  | Medos 2400 | HFOV (f=6Hz ΔP=40 MAP=9)     | 0.4                                   |                                    | 7.204 | 71.3 | 61.3 | 84 | SIMV               | 7 | 0.55 | 7.256 | 92.9 | 58.3 | 97 |
| 5  | Sorin      | APRV                           | 1                                     |                                    | 7.332 | 43   | 44.4 | 59 | SIMV               | 6 | 0.4 | 7.457 | 157  | 42.4 | 100 |
| 6  | Medos 2400 | APRV                           | 1                                     |                                    | 7.383 | 43   | 41.8 | 69 | SIMV               | 7 | 0.4 | 7.36  | 114  | 44.6 | 100 |
| 7  | Sorin      | APRV                           | 1                                     |                                    | 7.498 | 50.6 | 33.9 | 80 | SIMV               | 7 | 0.4 | 7.36  | 114  | 44.6 | 100 |
| 8  | Medos 2400 | HFOV (f=5Hz ΔP=48 MAP=23)     | 0.99                                  |                                    | 7.226 | 43.3 | 83.6 | 40 | SIMV               | 7 | 0.4 | 7.36  | 114  | 44.6 | 100 |

ECMO, extracorporeal membrane oxygenation; SIMV, synchronized intermittent mechanical ventilation; HFOV, high-frequency oscillatory ventilation; APRV, airway pressure release ventilation; PEEP, positive end-expiratory pressure; MAP, mean airway pressure; FIO₂, fraction of inspired oxygen; PaO₂, partial pressure of oxygen; PaCO₂, partial pressure of carbon dioxide; SpO₂, peripheral capillary oxygen saturation.
TABLE 4 | Comparisons of demographic and clinical features with the two groups.

| Variables | Severe adenovirus pneumonia (n = 8) | Common adenovirus pneumonia (n = 100) | p-value |
|-----------|------------------------------------|--------------------------------------|---------|
| Age (months) | 31.0 (19.5-51.3) | 19.0 (7.0-43.5) | 0.005 |
| Male (%) | 4/8 (50.0) | 61/100 (61.0) | 0.813 |
| T_max (°C) | 40.0 (39.9-40.7) | 39.8 (39.1-40.2) | 0.072 |
| WBC (10^3/L) | 5.1 (2.2-8.0) | 10.1 (6.6-13.5) | 0.008 |
| Neutrophil (%) | 77.4 (40.3-85.2) | 54.4 (30.9-68.0) | 0.105 |
| CRP (mg/L) | 53.0 (13.6-72.1) | 8.7 (1.7-25.4) | 0.022 |
| PCT (ng/ml) | 4.5 (1.0-21.0) | 0.3 (0.1-0.6) | 0.001 |
| LDH (U/L) | 1458.5 (834.8-3244.8) | 408.0 (282.0-639.0) | 0.001 |
| Pleural effusion (%) | 8/8 (100.0) | 13/100 (13.0) | <0.001 |

T_max, maximum temperature; WBC, white blood cell count; CRP, C-reactive protein (normal range, <8 mg/L); PCT, Procalcitonin (normal range, 0-0.46 ng/ml); LDH, lactate dehydrogenase (normal range, 110-295 U/L).

Risk factors of severe adenovirus pneumonia, which required ECMO support.

More and more researches supported that consolidations rather than interstitial infiltrates as the main radiological findings of adenovirus pneumonia. In our study, bilateral lobar or multifocal consolidations occurred in the lungs of all the 8 patients with severe adenovirus pneumonia. To date, adenovirus is the only virus known to cause focal or lobar consolidation as its main imaging characteristic (32), which resembles typical radiographic manifestation of bacterial pneumonia, and may mislead diagnosis. Nonetheless, the presence of wheeze, the diffuse nature of auscultatory abnormalities which were not confined to areas of consolidation, normal or decreased white blood cell counts, findings that include bilateral and multifocal involvement on chest radiographs, and progression of illness despite extensive antibiotic therapy, help to differentiate adenoviral from bacterial pneumonia (15, 34).

It has been noted that 14–60% of children with documented lower respiratory disease due to adenovirus have some degree of pulmonary sequelae (21, 35, 36). Compared with other viruses responsible for lower respiratory tract infections in childhood, adenovirus causes more severe respiratory and extra pulmonary manifestations (37) and is more prone to be followed by the development of BO (38). All the 6 survivors in our study have developed pulmonary sequelae, and BO (83.3%) was the most common manifestation. Plastic bronchitis was found in one patient, providing the rare case of HAdV infection-induced plastic bronchitis. Pulmonary fibrosis was observed in another patient, indicating the poor prognosis when it occurred in patients with adenovirus pneumonia.

Previous data analysis showed that for children requiring ECMO support for adenovirus infection, the survival rate was only 25% (39), the lowest among the viral types (11, 13, 31, 40), while another review of the Extracorporeal Life Support Organization Registry published in 2014 showed the survival rate at hospital discharge was 38% (41). It was demonstrated that early institution of ECMO in a ventilated patient was associated with improved survival, and late cannulation beyond 6 days was related to an increase in mortality (42, 43). Besides, Prolonged duration of ECMO support was supposed to be a risk factor of increased mortality (41, 42), which may be partly attributed to a great number of ECMO-related complications and the severity of the disease itself. In our group, the median duration of mechanical ventilation prior to initiation of ECMO was only 24.5 h. Although the longest duration of ECMO support was up to 86 days, the patient eventually died due to multiple organ failure, and the median duration on ECMO support was 9 days.

The survival rate (75%) of our 8 patients of severe adenovirus pneumonia associated with ARDS was higher compared to that in previous studies, which might be partly explained by the early institution of ECMO and the appropriate duration of ECMO support.

A number of complications occurred in our patients during the ECMO support, including bleeding, infection, pneumothorax, circuit clotting, hypertension, neurological dysfunction, and acute kidney injury, consistent well with the findings in the previous studies (41, 43, 44), and may represent the increased risk of maldistribution of oxygenated blood and systemic thromboembolism in patients supported on venoarterial ECMO (45). Venoarterial ECMO was demonstrated to be associated with more serious complications, e.g., cerebral infarction, seizures, and a higher mortality than venovenous ECMO (42, 45, 46). Nevertheless, because of the hemodynamic instability and/or cardiovascular dysfunction, the 8 patients with severe adenovirus pneumonia had to be placed on venoarterial ECMO. It was reasonable to hypothesize that the outcomes of these patients could potentially be better at institution with venovenous ECMO. Acute kidney injury was frequently present at the initiation of ECMO and had a significant association with increased duration of ECMO support and increased risk of mortality (47). In this context, concurrent continuous renal replacement therapy with ECMO was technically feasible and efficacious in the management of fluid overload and solute clearance (48). The use of antiviral agents to treat adenovirus is not well established. Cidofovir was supposed to be a therapeutic option in adenoviral ARDS (49), but its benefit had to be weighed against increased nephrotoxicity, and significant toxicity has so far limited its use more broadly (50). Actually, cidofovir is not available in most hospitals in China (51), including our hospital. The mainstay of treatment for patients with severe adenovirus pneumonia is still supportive, and ECMO would be applied when pediatric advanced life support steps are performed thoroughly without clinical response.

Our study has several limitations. First, our study was a single-center and retrospective study, and had a selection bias. Second, specific serotyping of adenovirus from our 5 cases was not available. Lastly, the number of cases in the present study is small, and a large-scale prospective study is urgently needed.

CONCLUSION

Our results showed that HAdVs could cause severe adenovirus pneumonia accompanied by ARDS in immunocompetent patients. Older age, markedly elevated levels of C-reactive
protein, procalcitonin, and lactate dehydrogenase may be the risk factors of severe adenovirus pneumonia requiring ECMO support. The promising outcome in our patients suggested that ECMO support should be instituted in the course of respiratory failure in children with severe adenovirus pneumonia, and may improve outcome.

**DATA AVAILABILITY STATEMENT**

All datasets generated for this study are included in the article/supplementary material.

**ETHICS STATEMENT**

The study has been approved by the Medical Ethical Committee of the Children’s Hospital of Zhejiang University School of Medicine (Hangzhou, China). The study does not contain tests or examinations. Written informed consents from the participants’ legal guardian/next of kin was not required to participate in this study in accordance with the national legislation and the institutional requirements.

**REFERENCES**

1. Lion T. Adenovirus infections in immunocompetent and immunocompromised patients. Clin Microbiol Rev. (2014) 27:441–62. doi: 10.1128/CMR.00116-13
2. Brandt CD, Kim HW, Vargosko AJ, Jeffries BC, Arrobio JO, Rindge B, et al. Infections in 18,000 infants and children in a controlled study of respiratory tract disease. I. Adenovirus pathogenicity in relation to serologic type and illness syndrome. Am J Epidemiol. (1969) 90:484–500.
3. Gupta P, Tobias JD, Goyal S, Hervie P, Harris JB, Sadot E, et al. Prolonged mechanical support in children with severe adenoviral infections: a case series and review of the literature. J Intensive Care Med. (2011) 26:267–72. doi: 10.1177/0885066610389963
4. Tang LF, Wang TL, Tang HF, Chen ZM. Viral pathogens of acute lower respiratory tract infection in China. Indian Pediatr. (2008) 45:971–5.
5. Gu L, Liu Z, Li X, Qu J, Guan W, Liu Y, et al. Severe community-acquired pneumonia caused by adenovirus type 11 in immunocompetent adults in Beijing. J Clin Virol. (2012) 54:295–301. doi: 10.1016/j.jcv.2012.04.018
6. Xu L, Liu J, Liu C, Duan Y, Zhu Y, Xu B, et al. Case-control study of the epidemiological and clinical features of human adenovirus 55 and human adenovirus 7 infection in children with acute lower respiratory tract infections in Beijing, China, 2008-2013. BMC Infect Dis. (2018) 18:634. doi: 10.1186/s12879-018-3520-z
7. Yao LH, Wang C, Wei TL, Wang H, Ma FL, Zheng IS. Human adenovirus among hospitalized children with respiratory tract infections in Beijing, China, 2017-2018. Virol J. (2019) 16:78. doi: 10.1186/s12985-019-1185-x
8. Cao B, Huang GH, Pu ZH, Qu JX, Yu XM, Zhu Z, et al. Emergence of community-acquired adenovirus type 55 as a cause of community-onset pneumonia. Chest. (2014) 145:79–86. doi: 10.1378/chest.13-1186
9. Yang Z, Zhu Z, Tang L, Wang L, Tan X, Yu P, et al. Genomic analyses of recombinant adenovirus type 11a in China. J Clin Microbiol. (2009) 47:3082–90. doi: 10.1128/JCM.00282-09
10. Sun B, He H, Wang Z, Qu J, Li X, Ban C, et al. Emergent severe acute respiratory distress syndrome caused by adenovirus type 55 in immunocompetent adults in 2013: a prospective observational study. Crit Care. (2014) 18:456. doi: 10.1186/s13054-014-0456-6
11. Ou ZY, Zeng QY, Wang FH, Xia HM, Lu JP, Xia JQ, et al. Retrospective study of adenovirus in autopsied pulmonary tissue of pediatric fatal pneumonia in South China. BMC Infect Dis. (2008) 8:122. doi: 10.1186/1471-2334-8-122
12. Ison MG, Hayden RT. Adenovirus. Microbiol Spectr. (2016) 4 :10.1128/microbiolspec.DMIH2-0020-2015
13. Meyer TA, Warner BW. Extracorporeal life support for the treatment of viral pneumonia: collective experience from the ELSo registry. Extracorporeal life support organization. J Pediatr Surg. (1997) 32:232–236. doi: 10.1016/s0022-3468(97)90185-8
14. Kim YJ, Hong JY, Lee HJ, Shin SH, Kim YK, Inada T, et al. Genome type analysis of adenovirus types 3 and 7 isolated during successive outbreaks of lower respiratory tract infections in children. J Clin Microbiol. (2003) 41:4594–9. doi: 10.1128/jcm.41.10.4594-4599.2003
15. Hong JY, Lee HJ, Piedra PA, Choi EH, Park KH, Koh YY, et al. Lower respiratory tract infections due to adenovirus in hospitalized Korean children: epidemiology, clinical features, and prognosis. Clin Infect Dis. (2001) 32:1423–9. doi: 10.1086/320146
16. Castro-Rodriguez JA, Daszenies C, Garcia M, Meyer R, Gonzales R. Adenovirus pneumonia in infants and factors for developing bronchiolitis obliterans: a 5-year follow-up. Pediatr Pulmonol. (2006) 41:947–53. doi: 10.1002/ppul.20472
17. Palomino MA, Larranaga C, Villagra E, Camacho J, Avendano LF. Adenovirus and respiratory syncytial virus-adenovirus mixed acute lower respiratory infections in Chilean infants. Pediatr Infect Dis J. (2005) 24:33–7. doi: 10.1097/01.pid.2005.24.1.72
18. Herbert FA, Wilkinson D, Burchak E, Morgante O. Adenovirus type 3 pneumonia causing lung damage in childhood. Can Med Assoc J. (1977) 116:271–4.
19. Becroft DM. Bronchiolitis obliterans, bronchiectasis, and other sequelae of adenovirus type 21 infection in young children. J Clin Pathol. (1971) 24:72–82. doi: 10.1136/jcp.24.1.72
20. Wenman WM, Pagtakhan RD, Reed MH, Chernick V, Albritton W. Adenovirus bronchiolitis in Manitoba: epidemiologic, clinical, and radiologic features. Chest. (1982) 81:605–9. doi: 10.1378/chest.81.5.605
21. Simila S, Linma O, Lanning P, Heikkinen E, Ala-Houhala M. Chronic lung damage caused by adenovirus type 7: a ten-year follow-up study. Chest. (1981) 80:127–31. doi: 10.1378/chest.80.2.127
22. Carrigan DR. Adenovirus infections in immunocompromised patients. Am J Med. (1997) 102:71–4. doi: 10.1016/s0002-9343(97)00015-6

**ACKNOWLEDGMENTS**

We are most grateful to the patients and their families.

**AUTHOR CONTRIBUTIONS**

XC analyzed the data and wrote the manuscript. JL, LQ, and CZ collected the data and followed up the prognosis. LT performed the study design and critical revision. All authors read and approved the final manuscript and agreed to be accountable for the content of the work.

**FUNDING**

This work was supported by National Natural Science Foundation of China (81170016 & 81470214) and Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents.
